Simon comes across as the practical hands on type that we would expect from a CTO. From what he's saying, the biochip use cases and competitors, the whole market is being assessed for the right killer application(s). This will require help from industry players. To identify a few uses in the areas of preventative and diagnostic care. Pharma and diagnostics companies have already done all the market research vis a vis what kind of devices are in demand. They also will have a future view of where the point of care industry is headed. So we don't have to do any of this ourselves.
Simultaneously the team is working on different ways of functionalising the sensors to bind to different bio markers. First one being potassium.
They're also starting the regulatory stuff, he mentioned FDA for the US market.
Also mentioned was the possibility of a partner adding our biosensor gFET tech to their portfolio, which essentially means IP is taken over or licensed exclusively. I would prefer this route. It means we don't have to jump through all the regulatory hoops ourselves. So really we have to start marketing demo devices as soon as practicable so that a client can see the potential of it and make an offer. Which is what Simon has on his to do list. When looking for a partner like this it's all about maximising the synergies and not about shareholder interests per se. But ROI for investors does come from these partnership deals. Let's see. Going to be very interesting to see who we are talking with. Something could come out of left field, while we conservatively prepare to wait another 12 to 24 months for very significant news on this front. Should be a busy time for updates.
AXE Price at posting:
23.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)